JAMA Network
About The Study: In this nationwide cohort study of patients with diabetes and prior major adverse limb events, treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) was associated with significantly lower risks of recurrent limb events, cardiovascular events, all-cause mortality, and kidney disease progression compared with dipeptidyl peptidase-4 inhibitors. These findings support the preferential use of GLP-1 RAs for secondary prevention in this high-risk population.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
